Because the number of novel TP53 missense variants has not increased significantly for several years now, it is assumed that a saturation plateau has been reached, with the discovery of all potential TP53 variants that sustain a defect in the protein’s tumor suppressor function21. This evidence concerns the gene TP53 and neoplasm.